DARK Classics in Chemical Neuroscience: Heroin and Desomorphine

Solid chip-based detection of trace morphine in solutions via portable surface-enhanced Raman spectroscopy

The accurate, sensitive and portable detection of morphine is important to handle judicial cases, but remains to be a great challenge. In this work, a flexible route is presented for the accurate identification and efficient detection of trace morphine in solutions based on surface-enhanced Raman spectroscopy (SERS) and a solid substrate/chip. A gold-coated jagged silicon nanoarray (Au-JSiNA) is designed and prepared via Si-based polystyrene colloidal template-reactive ion etching and sputtering deposition of Au. Such Au-JSiNA has three-dimensional nanostructure with good structural uniformity, high SERS activity and hydrophobic surface. Adopting this Au-JSiNA as SERS chip, trace morphine in solutions could be detected and identified in both dropping and soaking ways, and the limit of detection is below 10-4 mg/mL. Importantly, such chip is especially suitable for the detection of trace morphine in aqueous solutions and even domestic sewage. The good SERS performance is attributed to the high-density nanotips and nanogaps on this chip as well as its hydrophobic surface. Additionally, the appropriate surface modification of this Au-JSiNA chip with 3-mercapto-1-propanol or 3-mercaptopropionic acid/1-(3-dimethylaminopropyl)-3-ethylcarbodiimide can further increase its SERS performances to morphine. This work provides a facile route and practical solid chip for SERS detection of trace morphine in solutions, which is significant to develop the portable and reliable instruments for on-site analysis of drugs in solutions.

Surgical Treatment in Patients with Toxic Phosphorus Osteonecrosis of Facial Skull Middle Zone

During the last few years, in the territory of the Russian Federation, the number of cases of toxic phosphoric osteonecrosis of the jaws has increased against the background of taking drugs of "artisanal" production (pervitin, desomorphin). The aim of our study was to increase the effectiveness of surgical treatment of patients with a diagnosis of toxic phosphorus necrosis of the maxilla. We performed a comprehensive treatment of patients with a history of drug addiction and the above diagnosis. Surgical intervention in the volume of complete resection of pathologically altered tissues and reconstructive techniques using local tissues and a replaced flap made it possible to achieve good aesthetic and functional results in the early and late postoperative period. Thus, our proposed method of surgical treatment can be used in similar clinical situations.

A randomized controlled trial on the seeds of Sophora alopecuroides var. alopecuroides for the treatment of acute heroin withdrawal syndrome

BACKGROUND

and purpose: The seeds of Sophora alopecuroides var. alopecuroides have attenuated the acute opium withdrawal syndrome in humans. Therefore, the efficacy and safety of a standardized extract of the plant for the treatment of acute heroin withdrawal syndrome was evaluated in abstinent heroin addicts.

MATERIALS AND METHODS

The patients were randomized to take three 400 mg extract capsules (N = 50) or placebo (N = 50) once per day orally for eight days. The severity of withdrawal syndrome was assessed by the clinical opiate withdrawal scale (COWS) as the primary outcome measure at the baseline and on the days 3 and 8. The hepatic and renal functions and complete blood count were the secondary outcome measures tested at the baseline and end of the study.

RESULTS

The COWS score decreased in both groups after eight days, but the decrease was significantly higher in the experimental group (p < 0.001); the effect size of the decrease was 2.64. The groups had significant differences in the COWS scores on the days 3 and 8 (p < 0.001 for both). The extract had no significant effect on the other parameters. No side effect was noted.

CONCLUSION

The extract seems to alleviate acute heroin withdrawal syndrome safely.

Recent Chemical and Pharmacological Developments on 14-Oxygenated-N-methylmorphinan-6-ones

Adequate pain management, particularly chronic pain, remains a major challenge associated with modern-day medicine. Current pharmacotherapy offers unsatisfactory long-term solutions due to serious side effects related to the chronic administration of analgesic drugs. Morphine and structurally related derivatives (e.g., oxycodone, oxymorphone, buprenorphine) are highly effective opioid analgesics, mediating their effects via the activation of opioid receptors, with the mu-opioid receptor subtype as the primary molecular target. However, they also cause addiction and overdose deaths, which has led to a global opioid crisis in the last decades. Therefore, research efforts are needed to overcome the limitations of present pain therapies with the aim to improve treatment efficacy and to reduce complications. This review presents recent chemical and pharmacological advances on 14-oxygenated-N-methylmorphinan-6-ones, in the search of safer pain therapeutics. We focus on drug design strategies and structure-activity relationships on specific modifications in positions 5, 6, 14 and 17 on the morphinan skeleton, with the goal of aiding the discovery of opioid analgesics with more favorable pharmacological properties, potent analgesia and fewer undesirable effects. Targeted molecular modifications on the morphinan scaffold can afford novel opioids as bi- or multifunctional ligands targeting multiple opioid receptors, as attractive alternatives to mu-opioid receptor selective analgesics.

Enantioselective Isocyanide-based Multicomponent Reaction with Alkylidene Malonates and Phenols

A highly enantioselective isocyanide-based multicomponent reaction catalyzed by a chiral N,N'-dioxide/Mg^II complex was reported. A wide range of substrates were tolerated in this reaction, including alkyl- and aryl-substituted isocyanides with alkylidene malonates and various phenols, affording the corresponding phenoxyimidate products in good to excellent yields (up to 94% yield) with good to excellent enantioselectivities (up to 95.5:4.5 er). A catalytic cycle and transition state were proposed to rationalize the reaction process and enantiocontrol.

DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles

Etonitazene and related 2-benzylbenzimidazoles are potent analgetics invented in the research laboratories of the Swiss pharmaceutical giant CIBA in the late 1950s. Though the unprecedented structure distinguishes this class of compounds from poppy-derived and other synthetic analgetics, a range of studies indicate that these drugs are selective μ opioid receptor agonists possessing morphine-like pharmacotoxicological properties in animals as well as humans. Several unscheduled members of this synthetically readily accessible class of opioids that are not controlled under the international and national drug control systems have recently emerged on the illicit drug market. Among them, isotonitazene has been implicated in at least 200 fatalities in Europe and North America. None of the 2-benzylbenzimidazole derivatives have been developed into medicines, but etonitazene and some of its derivatives have been used as receptor probes and in addiction behavior studies in animals. The unique structure has inspired research on such benzimidazoles and related benzimidazolones of which "brorphine" made its debut as one of the newest psychoactive substance to emerge on the illicit opioid drug market in mid-2019. This in-depth review provides a historical introduction, an overview on the chemistry, pharmacological profiles, adverse effects, addiction liability, regulatory status, and the impact on chemical neuroscience of the 2-benzylbenzimidazoles. Structurally related benzimidazoles with opioid and/or analgesic properties are also discussed briefly.